|Articles|June 9, 2021
Supplements and Featured Publications
- Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum
- Volume 27
- Issue 10
Participating Faculty for Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum
Author(s)Jerry Bagel, MD, MS
Advertisement
FACULTY
Jerry Bagel, MD, MS
Director
Psoriasis Treatment Center of New Jersey
East Windsor, New Jersey
Clinical Professor
Icahn School of Medicine at Mount Sinai
New York, New York
FACULTY DISCLOSURES
Jerry Bagel, MD, MS, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
BOARD MEMBERSHIP
The National Psoriasis Foundation, Board of Directors
CONSULTANCIES OR PAID ADVISORY BOARDS
AbbVie, Janssen Pharmaceuticals, Arcutis Biotherapeutics
GRANTS RECEIVED
AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Novartis,
Sun Pharma, UCB
LECTURE FEES FOR SPEAKING AT THE INVITATION OF A COMMERCIAL SPONSOR
AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5

